Last reviewed · How we verify
HIV immune globulin solution
HIV immune globulin provides passive immunization by supplying antibodies against HIV to enhance immune response and potentially reduce viral load or transmission risk.
HIV immune globulin provides passive immunization by supplying antibodies against HIV to enhance immune response and potentially reduce viral load or transmission risk. Used for HIV infection (investigational), HIV prevention or post-exposure prophylaxis (investigational).
At a glance
| Generic name | HIV immune globulin solution |
|---|---|
| Also known as | HIVIGLOB |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Drug class | Immune globulin (polyclonal antibody preparation) |
| Target | HIV envelope proteins (gp120/gp41) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
This immunoglobulin product contains antibodies derived from HIV-infected or vaccinated donors that are pooled and processed into a solution for intravenous or intramuscular administration. It works by providing immediate, passive immunity through pre-formed antibodies that can neutralize HIV virions, enhance antibody-dependent cellular cytotoxicity (ADCC), and support the host's immune system in controlling HIV infection. This approach aims to augment the body's natural immune defenses against HIV.
Approved indications
- HIV infection (investigational)
- HIV prevention or post-exposure prophylaxis (investigational)
Common side effects
- Injection site reactions
- Fever
- Chills
- Headache
- Myalgia
Key clinical trials
- A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV (PHASE1)
- Combination Vaccination and Broadly Neutralising Antibody Therapy in HIV (PHASE2)
- Screening Strategies Among High-risk Populations for Anal Cancer (NA)
- ID93+GLA-SE Vaccine Against Tuberculosis in Older Adults Aged 55-74 (PHASE1)
- Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control (PHASE2)
- A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults (PHASE2)
- CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant (PHASE1, PHASE2)
- Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: